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Abstract 
Electronic health records (EHRs) can be a major tool in the quest to decrease costs and timelines 
of clinical trial research, generate better evidence for clinical decision-making, and advance 
healthcare. Over the past decade, EHRs have increasingly offered opportunities to speed up, 
streamline, and enhance clinical research. EHRs offer a wide range of possible uses in clinical 
trials, including assisting with pre-study feasibility assessment, patient recruitment, and data 
capture in care delivery. In order to fully appreciate these opportunities, healthcare stakeholders 
must come together to face critical challenges in leveraging EHR data, including data 
quality/completeness, information security, stakeholder engagement, and increasing the scale of 
research infrastructure and related governance. Leaders from academia, government, industry, 
and professional societies representing patient, provider, researcher, industry, and regulator 
perspectives convened the Leveraging EHR for Clinical Research Now! Think Tank in 
Washington, DC (February 18–19, 2016) to identify barriers to using EHR in clinical research 
and to generate potential solutions. Think tank members identified a broad range of issues 
surrounding the use of EHRs in research and proposed a variety of solutions. Recognizing the 
challenges, the participants identified the urgent need to look more deeply at previous efforts to 
use these data, share lessons learned, and develop a multi-disciplinary agenda for best practices 
for using EHR in clinical research. We report the proceedings from this think tank meeting in the 
following paper.  
Key words: electronic health records; clinical research; think tank meeting proceedings  
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Introduction 
An electronic health record (EHR) can be defined as a digital longitudinal repository of 
electronic health information about an individual patient that provides medical personnel with 
the information necessary for patient care and healthcare delivery.
1,2
 There is a growing need for 
efficient and cost-effective evidence that can guide real-world clinical decision-making; EHRs 
offer breakthrough opportunities to meet this need in clinical research. Since the enactment of 
the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009,
3
 
100% of hospital-based and 90% office-based physicians in the United States are now using 
EHRs, which is a five-fold increase in EHR adoption over the past eight years. Although EHRs 
are only one type of real-world data,
4
 the major shift toward physician and hospital EHR 
adoption coupled with recent technological advances, offers an unprecedented opportunity to 
make use of data routinely collected in EHRs to help answer questions about patient health.  
The widespread use of EHRs provides opportunities, but there are many challenges and 
considerations that need to be addressed before EHRs can be widely used in clinical trials. First, 
we must consider data quality. An ideal EHR would provide data that is relevant, accurate, 
complete, standardized, and in the correct format for clinical research, yet also accessible at a 
reasonable monetary and time-related cost; there currently remains a large gap between ideal and 
actual EHR data. Second, we must find appropriate methods for reducing bias and confounding. 
Third, in order to unlock EHRs’ full potential, we must tackle the technical, ethical, and cultural 
challenges that limit the efficient use of EHRs for research.
5
 Fourth, as clinical trial initiatives 
using EHRs evolve to include increased participant engagement, more complex informed 
consent, and increased need for data sharing, researchers will have to find ways to ethically 
involve patients, share data, and ensure that new research endeavors return value to trial 
5 
 
participants, clinicians, and researchers alike. Finally, from a regulatory perspective, we must 
consider what standards will be acceptable and applicable for broader use of real-world data. 
Given the myriad of EHR opportunities and challenges, leaders from academia, 
government, industry, and professional societies convened the Leveraging EHR for Clinical 
Research Now! Think Tank in Washington, DC (February 18–19, 2016) to identify the most 
pressing challenges facing the integration of EHR systems and data into clinical research; 
generate potential approaches for addressing these issues; and encourage efficient development 
of the relevant knowledge, personnel, and infrastructure necessary to maximize the integration of 
EHRs. This paper outlines the proceedings from this meeting. Although the primary focus of the 
paper concerns research within the United States (U.S.), many of the issues discussed are generic 
and will apply to healthcare systems internationally. 
 
Major challenges in use of EHR data 
The utility of EHRs in research will depend on many factors, including the specific type of 
research used, the kinds of questions that are asked, the clinical settings in which these questions 
are asked, the specific endpoints measured, the development phase of the drug or device being 
tested, whether the intervention is at the patient-, program-, or system-level, how well the types 
of required data are routinely captured in the EHR, and the study design. For example, depending 
on the study design, the extent of comorbidity data in the EHR may be suitable for identifying 
and recruiting patients for a clinical trial,
6,7
 but these data may not be accurate or complete 
enough to control for confounding in a comparative effectiveness medication study.
8
 Similarly, a 
randomized trial within an EHR system can assure more effective control of known and 
unknown confounders and can increase our confidence in any resulting causal inferences. In this 
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setting, problems of data quality should not lead to bias, but they could create variability that 
would mask treatment differences. The challenges outlined below address data quality and data 
access in terms of sharing data and patient consent, as well as questions about how best to 
engage clinicians in the research process. 
 
Understanding the quality of EHR data for clinical research 
EHR data are created to record a clinical interaction, serving as the longitudinal health record for 
a patient and fueling the administrative process of coding healthcare interactions for billing and 
system management purposes. There seems to be considerable overlap between the recorded 
patient outcomes and interventions, and the kind of events records in clinical trials, so efforts to 
use EHRs in clinical research are increasing and may facilitate the implementation of blinded 
randomized controlled trials. At the same time, concerns arise about whether the quality of the 
data is suitable for research.
5,9
 The quality of EHR data directly impacts the research that may 
follow, and can be illustrated by our ability to characterize missingness. That is, can we tell 
whose data are missing from the EHR or what types of data are missing? What is the best way to 
characterize the population, interventions, covariates, and outcomes of interest in a way that is 
complete and accurate?  
 
Characterizing the study population 
If we define a population as those people who interact with a given healthcare system, then a 
population observed in EHRs may actually be more representative of the general population than 
a typical clinical trial study group. On the other hand, there is some potential selection of a non-
representative population, depending on who is approached for a clinical trial and who consents 
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to participate. Often, clinical trial participants are healthier than the broader population (i.e., non-
trial participants who also have the condition of interest) and this could be true of EHR-identified 
patient populations. Alternatively, populations that are in contact with healthcare systems (and, 
therefore, included in EHR data) do not represent a random sample of the underlying 
population
10
; rather, people in more frequent contact with healthcare systems tend to be sicker 
and are more likely to be insured.
11
 In addition, an EHR does not typically indicate accurate 
information about when a given person would be observable for a research study (e.g., an entry 
date may be recorded, but an exit date [when a person no longer would seek care at that health 
system] is not). As a result, unlike clinical trial data (where entry and exit dates correspond to the 
study start and stop dates) or insurance claims data (where entry and exit dates are tied to the 
dates of enrollment), EHR data in the U.S. do not include well-characterized entry and exit data 
for a given population. Consequently, a clinical trial that uses EHR data would need to consider 
the collection of additional individual data about follow-up and patient status during study 
time.
12
 
 
Characterizing the interventions and outcomes 
The types of EHR data that are available for individuals in a given population pose a challenge 
for clinical research. An EHR may record factors related to a clinical visit, but the types of 
details captured may be systematically influenced by the subsequent use of these records for 
billing purposes; therefore, an EHR may be less likely to reflect the determinants of care that are 
relevant to research goals. For example, problem lists may be sufficient for clinical decisions and 
administrative purposes, but not detailed enough for a researcher to determine the onset date of a 
given comorbidity. Similarly, an EHR text field that indicates a diagnosis may be sufficient for 
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clinical care, but would not show the criteria used to determine the diagnosis, nor would the text 
field reflect the absence of a diagnosis—both of which are necessary when considering data use 
in a clinical trial setting.  
Additionally, patient-reported outcomes (PROs) may be used in studies to measure the 
impact of interventions, but PRO data may not be included in EHR. If PRO data are included, 
then they are typically not codified
13
 or routinely collected as part of healthcare delivery, which 
makes the prospect of using this information for research purposes quite difficult. PROs, or other 
study-specific tests (such as exercise tests), could not be a study endpoint unless special efforts 
were made to incorporate these study-specific tests either as part of the trial procedures or 
routinely as part of clinical practice requirements. Finally, documentation about clinical 
decisions is usually omitted from EHRs; therefore, clinical researchers for observational studies 
must infer a provider’s rationale (e.g., indications, contraindications) and are not able to include 
or quantify the influence of family and patient preferences on healthcare decision-making and 
outcomes.  
EHR data sources that exist in other countries (Table 1) often include unique personal 
identifiers that allow the linkage of healthcare data to national population, census, and education 
registries; however, the U.S. does not have this type of data, nor the capability to easily perform 
these types of linkages. Consequently, we are limited in our ability to account for confounding 
by non-healthcare determinants of health, such as employment status, contact with the judicial 
system, or a person’s housing/location.  
All types of health data are compromised by coding errors and inconsistencies across 
providers and time; however, the unique state of fragmentation within the U.S. healthcare system 
results in EHR data that lack vital information about the care a patient receives outside of a given 
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healthcare system. Furthermore, if such data are included, they may be incomplete or 
inaccessible. Without interoperability between different healthcare systems, the extent to which 
an individual receives care at other facilities is unknown for most EHR systems.  
The Meaningful Use program was designed to encourage eligible professionals and 
hospitals to successfully demonstrate meaningful use of EHRs in order to qualify for incentive 
payments.
18
 Meaningful Use, and other programs of this kind, were created to increase 
interoperability between health systems, yet a large portion of the sophisticated, detailed patient 
information encouraged in these programs are unstructured text or images.
19
 As a result, patient 
information is not easily accessible or standardizable for clinical research. In particular, 
behavioral and mental health information are likely to be missing from the research data, 
especially if these data were not ascertained using systematized measures (Table 2).
20 
 
Challenges to sharing EHR data 
EHR data in the U.S. reflects at best a poorly coordinated or fragmented system. In order for us 
to leverage our health data into a useful tool for interventional and observational research, data 
sharing is vital to creating data sources that are complete and accurate. There are several ways to 
increase the utility of a single system’s EHR data, including linking datasets to the birth and 
death index, to existing registries for specialized cohorts, to private and public insurance claims 
data, and (perhaps most importantly) to other EHRs that may have complementary data.
21
 
However, there are challenges to developing a scalable infrastructure for data linking to conduct 
EHR research across multiple institutions. First, there is often a lack of standardized data 
elements, which require a common understanding of the meaning and format of the data, as well 
as logical, technical, and information security concerns. Second, EHR data can present complex 
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ethical questions and can cause difficulty reconciling the often competing interests of the various 
data stewards and researchers.
22,23
 Finally, although awareness and understanding of patient 
perspectives about the use of the EHR for clinical research is growing, there remains a lack of 
understanding from the patient perspective regarding linking to other data sources.
24
 All of these 
challenges hinder the development of large-scale research projects that could fully leverage the 
diverse wealth of clinical data to generate new health-related knowledge. 
 
Emerging dimensions of patient consent and involvement 
Patient consent in EHR research 
EHR data are collected primarily for use in the clinical setting. Accordingly, the consent 
obtained by the health system from the patient generally applies only to the use of these data for 
clinical care and other operational purposes. Consent is typically not required when patient data 
are used by the health system to optimize care delivery though quality improvement initiatives, 
by payers to optimize their business, or by clinical researchers. In traditional clinical research, 
including trials, the consent that is obtained at the start of the trial governs the collection of study 
data, which is generally gathered from the patient at standalone clinical visits via a dedicated 
electronic case report form (eCRF). Increasingly, as pragmatic clinical trial study designs emerge 
and data are collected in the course of regular healthcare, many questions arise about the type 
and extent of patient consent that should govern these activities.
25
 There is growing concern that 
the current ethical standards around consent for using EHR data for clinical research are limiting 
the generalizability of research results (e.g., selection of research participants) and increasing 
research costs.
26,27
 Furthermore, when presented with new ways of using EHR data for 
prospective research, patients may have reservations about whether their health data are being 
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used for profit purposes or in ways they would not permit if they were fully informed. Rather 
than creating standalone research datasets, clinical research increasingly involves the 
development of registries and data repositories that can serve as platforms for a broad range of 
future research uses, including linkage to other data sources. Uncertainty exists about the best 
way to obtain patient consent for ongoing secondary use of such data, since future research 
projects cannot usually be identified at the time of initial consent. These concerns suggest that 
traditional approaches to obtaining patient consent data may not be appropriate for EHR 
research.  
 
Other types of patient involvement in EHR research 
Looking beyond the initial consent issues, patient involvement in EHR-based clinical research 
includes the ways in which patients are contacted for research purposes via the EHR, how data 
are collected from these patients, what access is permitted to the research data within the EHR, 
and how EHR systems can be used to share research results with participants. Since clinical 
research often uses information held within the EHR to define and construct study cohorts, 
requests to the patient for research involvement are increasingly common, but risk overwhelming 
potential participants. Once enrolled in a study, patients may provide data at routine medical care 
visits through web portals or their own wearable medical devices; both of these technologies 
introduce a new layer of contextual data about the patient between clinic visits. Many questions 
remain unanswered regarding patients’ readiness to make these data available, the reliability of 
sources, and the data’s ultimate purpose in clinical research. As our understanding of controlling 
EHR data shifts from an ownership model to one of data stewardship, we must delineate a 
patient’s ability and preference to view, edit, and participate in the secondary uses of EHR.28 
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Finally, most research results currently exist in the form of products directed toward clinicians 
and researchers, with the anticipation that trickle-down effects will result in practice change. If 
these research results are directed at patients, then they are often in the form of standalone web 
sites or educational materials, rather than integrated into the EHR. For each of these domains, 
there is wide variability in how patients, health systems, and researchers interact. Only recently 
has evidence emerged about the best practices for eliciting EHR research-related patient 
preferences and priorities.  
 
Engaging clinicians in EHR research  
Clinical research is increasingly taking place in real-world settings. As a result, in pragmatic 
clinical trials embedded in learning health systems that rely upon EHR, the importance of the 
clinician’s role increases. In the course of daily clinical care, non-researcher clinicians are often 
involved in many research activities that require interaction with EHR; these activities include 
obtaining access to and recruitment of patients, education and obtaining informed consent, 
implementation of the protocol, definition and collection of data elements from clinical practice, 
and generating the initial clinical research questions.  
Clinician engagement is critical to all successful interventional research, but engagement 
may be particularly difficult in pragmatic clinical trials,
29
 because of a clinician’s focus on the 
complexities of clinical practice rather than research participation, as well as the financial 
implications of time not spent on clinical activities.
30
 Clinician engagement can be influenced by 
the clinician (e.g., belief in the importance of the study, appropriate training, and 
communication), clinical site (e.g., utilizing effective study champions, staffing, flexibility to 
accommodate clinical processes, and priorities), and health system leadership (e.g., culture of 
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support for research, incentives, and allowances for clinicians, as well as effective 
communication channels).
31,32
 One of the barriers to using EHR in clinical research is the lack of 
a clear incentive structure to encourage clinician involvement in EHR research, as well as little 
understanding of the necessary requirements to encourage effective clinician participation.
33
   
 
Approaches and future directions  
There are examples of successful approaches to address the challenges we have outlined 
so far, but few of these approaches have spanned institutions. Some of the suggested and existing 
approaches are outlined in the sections below (Table 3). 
 
Building EHRs to capture research-quality data  
Since EHR data are not created for purposes of clinical research, numerous challenges 
arise from the structure, content, form, and completeness of these data. A solution would involve 
producing EHR data in a way that is more suitable for clinical research. Specifically, if clinical 
research was considered a co-primary use of EHR systems and data, research purposes could be 
considered in upstream engineering decisions about EHR structure and function. The current 
movement towards evidence-generating medicine
34
 embodies the concept of building research 
considerations into the planning, organization, and function of healthcare systems.
35
 Point-of-
care trials are a research method that adapts the existing structure and function of EHR to recruit 
and randomize patients, as well as to ascertain outcomes.
36
 In a point-of-care trial, research 
activities are incorporated into the everyday clinical work flow, and the ongoing results are 
immediately able to be implemented into practice. Clinician collaborations with professional 
EHR specialists have resulted in sets of EHR-derived data elements in specific disease areas that 
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include endpoints that are useful to both clinicians and researchers,
37 
and that do not unduly 
increase collection burden. This type of collaborative approach can help both clinicians and 
researchers appreciate EHR as a tool for generating and using data for evidence-based clinical 
practice. 
 
Developing empirical research about EHR data quality 
Empirical research about EHR data quality is critical. For example, EHR data have been 
validated for completeness against claims data for the provision of diabetes and general 
preventative services.
38,39
 Concordance between EHR and claims data was higher depending on 
patient characteristics (e.g., continuous insurance coverage) and type of service (e.g., vaccination 
or cancer screening that are both covered by insurance do not need additional referrals). 
Although data quality assessment frameworks exist,
40–42
 there needs to be further study of how 
data from clinical trials compare to EHR data from the same patients. An increasing number of 
researchers have compared adjudicated clinical trials events to EHR data-ascertained events, 
reporting important differences between event rates, as well as relatively consistent agreement 
between the intervention effect measured in both data sources 
43–45
 As there may also be 
differences in the quality of data in different therapeutic areas (e.g., cardiovascular outcomes vs. 
psychiatric outcomes), these comparisons are needed in a variety of patient populations. 
Encouraging groups conducting studies to make EHR data quality assessment a part of research 
reporting will generate more information on how quality may impact findings.
8,46
 
 
Sharing data 
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With the hope of using the diverse wealth of clinical data to maximize new health knowledge, 
several initiatives have been started to address the technical issues inherent to large-scale data 
sharing, including the Sentinel Initiative, PCORnet,
47
 the Observational Health Data Sciences 
and Informatics (OHDSI) program, and a European initiative called the Electronic Health 
Records for Clinical Research (EHR4CR) project.
48,49
 In the context of many healthcare systems, 
these initiatives have found ways to securely perform the following tasks: 1) distribute queries 
from authorized researchers through network software; 2) execute the queries against the local 
data; and 3) return aggregated results to the researcher.
47,50
 Concurrent with interoperability 
efforts in technology and clinical data standards,
51
 these distributed research networks use 
common data models to harmonize codified elements to be included in datasets. In this way, 
these networks are able to link disparate data to increase the scale of each research study. 
On a more local level, linkages between diverse data sources have occurred in the past on 
an ad hoc basis; however, the time-intensive process of establishing appropriate governance for 
the numerous privacy and information security concerns prevents the scaling up of this kind of 
data sharing. One response to this dilemma has been to establish honest broker systems, which, 
at their simplest, are methods allowing for reliable linkage of health data among clinical or 
research entities. An honest broker facilitates the sharing of data for both clinical and research 
purposes, maintains a master file of participant identities, and creates de-identified datasets for 
research.
52
 
The traditional culture among health researchers is only to make the findings from their 
research available to the public in a timely manner, but not the raw data; however, as mandated 
by many public granting agencies, access to raw data is increasingly being granted. This level of 
access creates the potential for other researchers to verify results, inquire into new research 
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questions, or perform meta-analyses using raw data from multiple studies. The access must be 
accompanied by proper oversight, so that the researchers new to the data understand its strengths 
and limitations. Nevertheless, this new culture of open data sharing may be hindered by 
motivations to control access to data, either for reasons of research productivity or 
commercialization and/or intellectual property potential.
53
 These perspectives can be countered 
by gradually changing how researchers measure data impact, so that the creation of datasets is 
valued and rewarded.
54
  
Finally, empirical research is needed to understand how patients feel about their personal 
data being shared for research purposes. Retrospective research is often exempt from patient 
consent, due to the practical difficulty of contacting patients months or years after data creation, 
as well as the potential for selection of a non-representative population because of the exclusion 
of those patients who did not consent. Academic research is also considered separate from both 
quality improvement and public health activities, which are generally exempt from requiring 
patient consent and ethical evaluation. Yet as the boundaries become increasingly blurred 
between activities that traditionally require consent and those that do not, we need to better 
understand the patient’s perspective and be able to describe to stakeholders the intended use of 
medical records.
55,56
 A greater awareness of the potential uses of health data, along with the care 
of individuals, could lead to alternative models of consent for the collection, storing, and sharing 
of data. 
 
Building a culture of trust  
To enable EHR use in clinical research, efficiently obtaining patient consent is necessary. 
Nevertheless, the operational aspects of this process must be built upon a culture of trust; 
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specifically, there must be a strong relationship between clinicians, health systems, patients, 
researchers, and participants. One way of building trust may be to increase patients’ awareness of 
how their EHR data serve the public and common good. An example of such an approach comes 
from the United Kingdom (UK), where EHR data has been collated on a national level for 
decades and the general public has an understanding that secondary use of the data, including 
linkages to other sources, is for societal benefit.
26
 The West of Scotland Coronary Prevention 
Study (WOSCOPS) was a randomized cardiovascular outcome trial of pravastatin that extended 
follow-up through the use of administrative data. The UK study survived many regulatory and 
ethical oversight changes and was able to publish 20-year results.
57
 More recently, UK 
researchers examined patients’ understanding of EHR and consent preferences, describing the 
distribution of preferences found among lay people and patients, and recommending awareness 
activities for specific target groups about the value and use of EHR in clinical research.
55
 
Research and education that is similar to what the UK has undertaken could be adapted 
for domestic use in order to increase the public value of secondary research and decrease the 
barriers related to consent. Yet given the role of private and for-profit entities within U.S. 
healthcare, there are unique challenges to building an environment that supports trust among all 
stakeholders, patients, clinicians, healthcare systems, drug and device companies, and EHR data 
system vendors. Transparency about profits resulting from patients’ health data would increase 
the potential for trust.
58
 Trust can also be facilitated by implementing technological solutions that 
preserve patient privacy, such as distributed networks that use data only under the protection of 
institutional firewalls.
47
 
Operationally, eliciting the right consent for research projects at the correct time may 
mean building processes within the structure of EHR data that capture patient consent, ideally at 
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the time of registration with the health care system.
59
 Currently, for some observational research 
using EHR data sources, such as the Sentinel Initiative, the need for individual patient consent 
has been waived as they were considered public health practice activities. However, other 
solutions would need to be established to elicit more specific consent for prospective or 
interventional research. Examples of EHR-integrated patient consent dashboards are 
demonstrating how patients can be active stewards of their own data, as well as controlling and 
managing consent and permissions.
60
 
Lastly, sharing with patients the clinical research results stemming from their 
involvement in EHR, face-to-face clinic visits that focus on engaging the patient in their care, 
and in-person contact with an individual who represents the research institution may all be ways 
of facilitating a culture of trust between patients and researchers. 
 
Targeting clinician engagement  
Several helpful observations emerge from research on the perceptions and preferences of 
clinicians with regard to their role in EHR-based research. Including clinicians in the research 
process from the point of conception through results dissemination may be a means to engage 
clinicians in EHR research. Learning from clinicians about their daily practice realities and 
preferences would allow for the development of mutually feasible study protocols. Providing the 
simultaneous support of site leadership is also important for clinicians to feel supported in their 
research roles.
61
  
 Unlike the traditional clinical trial model, where sites are reimbursed for their 
involvement, pragmatic trials using EHR and clinicians as the backbone of the data collection 
methods require mutually beneficial relationships.
31
 Non-financial incentives have been 
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recommended to engage clinicians in EHR studies including population management EHR 
interface tools that provide clinicians with a bigger picture of patient health and practice 
patterns,
62
 or certification programs for non-researcher clinicians who participate in research. 
Practical activities during a trial may include an introduction letter that outlines the benefits of 
participation, site visits to all facilities to talk with frontline workers, in-person training sessions 
of involved clinicians, a regular schedule of ongoing activities (such as regular coaching calls for 
site unit champions), and return visits to underperforming sites. Despite these recommendations, 
questions still exist about clinician engagement including what resources are needed to enable an 
ideal level of clinician engagement, what practices have been shown to work, and what methods 
can engage clinicians efficiently in larger-scale projects. 
 
Conclusions 
The challenges and approaches to integrating EHR data into medical research that are presented 
in this paper focus on the research endeavor, improving quality and accessibility to maximize the 
use of these data, and the experiences of the research participants (including patients and 
clinicians). Robust research results that originate from EHR data could be more generalizable to 
the types of patients that clinicians see every day. Nevertheless, for these results to actually 
impact clinical care, we will need to build upon the constantly evolving discussion about the 
conditions and requirements under which EHR research results would meet regulatory 
standards.
63,64
 When randomization can be embedded within the care system and EHR data is of 
sufficient quality with complete outcomes, then a number of stakeholders will be able to make 
decisions based on the results. To ensure successful use of EHR data, trial data would still need 
to be evaluated according to data integrity standards, accuracy, and provenance in order to meet 
20 
 
regulatory framework goals. Addressing the challenges outlined in this paper can help ensure 
that future clinical research is more efficient, affordable, and relevant to clinical decision-
making. Ultimately, finding solutions to these challenges will secure our continued progress 
towards improving the health and care of the populations we serve. 
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Table 1. International EHR examples 
 
Denmark: All Danish citizens have a unique personal identification number; therefore linkage at 
the individual level between a number of long-standing country-wide registries is possible. In 
addition to a cause of death registry, health care (hospital care, prescription (dispensed), and 
condition specific (heart, diabetes, cancer) registries are available. Danish registries on economic 
and social issues include registries containing data about education, employment, income, and 
housing. Datasets are stored at Statistics Denmark, from which individual level data are available 
for online access by Danish institution affiliated researchers.
14
   
Singapore: The national electronic health record (NEHR) uses a unique national identifier 
number to link longitudinal data from registries and administrative and medical records at 
hospitals and clinics to create a single health care record for each person. Clinicians have real-
time access to a view-only summary of the most recent interactions with the health care system, 
including clinical events, investigation reports, alerts, emergency and hospitalizations, 
medications and allergies. Access to additional detailed reports is possible using a record locator 
system. Integration of legacy systems into the NEHR started in 2011, and will grow to support 
services such as the call centers, telehealth, and personal health management. Research using the 
NEHR has begun.
15
  
Sweden: Sweden’s electronic health data collection system is facilitated by a unique identifier 
for each resident. This unique number allows linkage between a number of mandatory Swedish 
registers (population registry, census, education registry, prescription registry, in-patient and out-
patient health care registry, cancer registry, cause of death registry). In addition to the mandatory 
patient registies there are a number of clinical registries that aim to measure and enhance quality 
care. For example, the SWEDEHEART registry is a national health care registry for heart 
disease, reporting data about baseline characteristics, procedures, and outcomes of patients 
hospitalized for coronary and valve care. Various features facilitate the online entry of quality 
data, including data checks, auto-populated fields and calculated variables. In addition, automatic 
linkage with the population registries allows data about name and sex, and the personal 
identification number allows for complete longitudinal follow-up. These EHR data are being 
used for traditional epidemiological research as well as registry based trials.
16
 
UK: The National Health Service in the United Kingdom has had a long history of the use of 
32 
 
electronic patient care records, especially at the primary care level. Most of the population is 
registered with a single general practice, which serves as the gatekeeper to the rest of the system. 
Most prescription and hospitalization data are gathered and added to the record. This has allowed 
the construction of research datasets from the data of participating general practices,
17
 and 
recently more integration of data from primary, secondary and tertiary care.  
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Table 2. Research implications of EHR data characteristics 
 EHR data feature Research implications Applicable 
for 
randomized 
trials 
Applicable to 
observational 
studies 
Characterizing 
the correct 
population   
 Population 
coverage/definition 
 Difficulty in defining 
entry and exit from 
population 
 Extent of external 
generalizability  
 Affects available study 
time and capture of 
baseline characteristics 
and outcomes 
 Affects measurement of 
long term health states 
    
Characterizing 
the 
interventions 
and outcomes - 
what types of 
data are 
missing? 
 
 Data recorded for 
clinical purposes 
 Clinical decision 
making process not 
well reflected 
 Patient reported 
outcomes, social 
and psychological 
data are not 
included 
 Does not capture 
sufficient detail at the 
correct time to estimate 
exposure/outcome 
/confounders 
 Difficult to evaluate data 
errors, determine causal 
mechanisms or generate 
next research question or 
appropriate intervention  
 Research results may be 
systematically biased due 
to missing subjective, self-
report or preference data 
    
Characterizing 
the 
interventions 
 Fragmentation of 
EHR data across 
providers 
 Risk of ascertainment and  
misclassification bias 
 Multiple data sources may 
    
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and outcomes – 
are the data 
included 
complete, 
correct and 
accessible? 
 Lack of 
interoperability 
between systems 
and locked 
narrative text 
(missing data) 
 Completeness of 
data types and 
fields 
be needed for validation 
 Missingness can be at 
random or informative, 
methods to mitigate have 
not been established 
 Range of exposures, 
outcomes and confounders 
of interest may be limited. 
Effect estimates may be 
biased, and this bias may 
differ by condition and 
type of data used. 
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Table 3. Challenges and approaches to the use of EHR for clinical research 
 Challenges Approaches 
Data quality 
 
 For available data – 
concerns about 
incompleteness and 
missingness 
 Selection bias – who is 
represented in EHR data 
during what time period 
 Lack of meaningful patient-
reported data, lack of 
documentation about 
decision making 
 
 
 Integrate research functions into 
the EHR to improve quality data – 
evidence generating medicine 
paradigm 
 Prioritize research about EHR data 
quality– treat process and 
regulations as empirical questions 
 
 
Data sharing 
 
 Clarity about elements that 
are needed for data sharing 
include meaning and 
usefulness of the data, and 
governance requirements 
 Lack of understanding about 
patient perspectives of data 
sharing 
 Use distributed research networks; 
PCORnet, Sentinel 
 Development of scalable methods 
to use identifiers to link disparate 
data while preserving privacy  
 Create incentives for data sharing 
 Research about patient consent 
preferences in data sharing/linking 
Patient consent and 
involvement 
 
 Uncertainty about obtaining 
patient consent for ongoing 
secondary use of data 
 Ownership and access to 
patient data 
 How to contact and engage 
patients about the use and 
 Increase value of research as a 
public good (international 
examples) 
 Build a trust environment  
 Demonstrate transparency about 
profit over time from patients’ data 
 Utilize technological solutions to 
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results of their data preserve privacy 
Clinician 
engagement 
 Clinician engagement is 
limited by time, money, and 
interest 
 Lack of an incentive 
structure to encourage 
clinician engagement 
 
 Build a common ground between 
the goals of clinician and 
researchers - non-financial 
incentives such as population 
management tools/clinical 
interface, or certification programs 
for participation in research 
 Share examples of sustainable 
methods to engage clinicians 
 
